Whether PharmaEssentia Korea’s new drug for polycythemia vera, ‘BESREMi,’ will be listed with reimbursement in Korea is gaining attention.

The drug was approved for hydroxyurea-refractory or intolerant polycythemia vera in March last year but failed to overcome the CDDC barrier in July of the same year.

At that time, the CDDC determined that there was insufficient evidence to determine the clinical utility of BESREMi as a second-line treatment.

In response, PharmaEssentia resubmitted its application for reimbursement in March after adding domestic clinical data on BESREMi and supplementing the evidence on the drug’s efficacy in second-line therapy. As 50,000 pe